New antibody TST001 targets Hard-to-Treat cancers in early trial
NCT ID NCT04396821
First seen Jan 10, 2026 · Last updated May 13, 2026 · Updated 14 times
Summary
This early-phase trial tests a new drug called TST001, an antibody that targets a protein (CLDN18.2) found on some cancer cells. It is being studied alone or with other treatments in about 150 people with advanced stomach, esophageal, or pancreatic cancers that have not responded to standard therapy. The main goals are to check safety, find the best dose, and see if it helps shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Allegheny Hospital
Pittsburgh, Pennsylvania, 15212, United States
-
Banner MD Anderson
Gilbert, Arizona, 85234, United States
-
Emory University
Atlanta, Georgia, 30033, United States
-
Florida Cancer Specialists
Sarasota, Florida, 34232, United States
-
Gabrail Cancer Research
Canton, Ohio, 44718, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Memorial Sloan Kettering
New York, New York, 10065, United States
-
NEXT Oncology
Austin, Texas, 78704, United States
-
Pennsylvania Cancer Specialist Research Institute
Gettysburg, Pennsylvania, 17325, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Stony Brook Cancer Center
Stony Brook, New York, 11794, United States
-
Swedish Cancer Institute
Seattle, Washington, 98104, United States
-
University of Arizona
Tucson, Arizona, 85724, United States
-
University of Kansas, School of Medicine
Kansas City, Kansas, 66160, United States
-
Vanderbilt University
Nashville, Tennessee, 37232, United States
-
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, 27157, United States
-
Washington University
St Louis, Missouri, 63110, United States
-
Yale University
New Haven, Connecticut, 06519, United States
Conditions
Explore the condition pages connected to this study.